Novartis plans to invest $23 billion over the next five years to expand its U.S. operations, including building six new factories and enhancing three existing ones, along with establishing a new research hub. This expansion aims to ensure that all medicines for U.S. patients are produced domestically amid current trade uncertainties. The initiative will significantly increase Novartis’ capital spending, allowing it to manufacture complex medicines and create a biomedical research hub in San Diego, scheduled to open by 2029, reinforcing its commitment to U.S. growth.

Source: https://www.supplychaindive.com/news/novartis-23-billion-us-manufacturing-new-drug-plants/745100/